HOW SCIENTIFIC IDEAS BECOME MEDICINES

For an idea to travel from a university laboratory to a patient's bedside is long and difficult. In this special double-header, Eliot sits down with two people who see that journey from opposite ends of the table.First, Professor Chas Bountra, former Pro-Vice-Chancellor for Innovation at the University of Oxford, explains how Oxford rewired its own culture to become the UK's most productive innovation engine. The story includes two unicorn acquisitions, the deliberate equity reform that unlocked academic ambition, and the moonshot question driving the next chapter: when will the UK build its first trillion-pound company?Then, Emma Johnson takes us inside the investor's room. A neuroscientist by training and now a leading UK life sciences venture investor, Emma explains how venture capital actually works, how she decides whether a scientific idea is worth millions, and the single trait she values above all others in a founder.Together, two halves of the same story, and a clear-eyed, hopeful conversation for anyone curious about how science becomes a meaningful impact in the real world.CHAPTERS: 01:56 – Chas Bountra 05:08 – Inside drug discovery at GSK: why 90% of ideas fail 09:30 – Rewiring a university for innovation 11:32 – The equity reform that unlocked academic entrepreneurship 15:00 – Two unicorn exits 16:32 – Building an ecosystem: people, capital, ambition 17:30 – How does the UK compete with the US, China and India? 19:48 – Anti-science, AI, and anticipating the downsides of new tech 24:32 – Emma Johnson 25:44 – From neuroscience to venture capital 27:21 – What "venture" actually means 29:54 – How venture capital funds are structured: LPs, GPs and returns 33:51 – Inside the British Business Bank and the Future Fund: Breakthrough 36:47 – What makes a UK biotech globally competitive 40:39 – How an investor assesses a scientific pitch 48:16 – When investors say no 51:24 – The traits that matter in a biotech founder 54:17 – There is no straight line to success 55:48 – What success really looks like from the investor's seatFOLLOW THE GUESTS:Professor Chas Bountra: https://www.linkedin.com/in/chas-bountra-72b9991/Emma Johnson: https://www.linkedin.com/in/emma-johnson-life-sciences/This podcast was produced by Crisis What Crisis Productions. With special thanks to Mintz: life sciences lawyers who help turn scientific breakthroughs into reality. https://www.mintz.com